Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38.
Jun 3, 2015Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Jun 3, 2015Br J Clin Pharmacol 2015; 80:128-38
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C
Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival
Siano M (2015). Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival.
Jun 2, 2015Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival
Jun 2, 2015ASCO 2015
Siano Marco
On Nonharming: The Debate Continues in Stage I Testicular Cancer
Gillessen Sommer S, De Santis M, Rothermundt C. On Nonharming: The Debate Continues in Stage I Testicular Cancer. J Clin Oncol 2015
Jun 1, 2015On Nonharming: The Debate Continues in Stage I Testicular Cancer
Jun 1, 2015J Clin Oncol 2015
Gillessen Sommer Silke, De Santis Maria, Rothermundt Christian
Sequence of treatment in locally advanced and metastatic renal cell carcinoma
Fischer S, Gillessen Sommer S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015; 4:310-25.
Jun 1, 2015Sequence of treatment in locally advanced and metastatic renal cell carcinoma
Jun 1, 2015Transl Androl Urol 2015; 4:310-25
Fischer Stefanie, Gillessen Sommer Silke, Rothermundt Christian
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Frauenheilkd 2015; 75:574-583.
Jun 1, 2015Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Jun 1, 2015Geburtshilfe Frauenheilkd 2015; 75:574-583
Schneeweiss A, Ruckhäberle E, Huober Jens
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner C, Klein C, Liu N, Hallek M, Frenzel L, Krause G. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer 2015; 137:2234-42.
May 12, 2015Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
May 12, 2015Int J Cancer 2015; 137:2234-42
Göckeritz Elisa, Kerwien Susan, Baumann Michael, Wigger Marion, Vondey Verena, Neumann Lars, Landwehr Thomas, Wendtner Clemens M, Klein Christian, Liu Ningshu, Hallek Michael, Frenzel Lukas P, Krause Günter
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26:1533-46.
May 4, 2015-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
May 4, 2015Ann Oncol 2015; 26:1533-46
Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.
May 3, 2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 3, 2015Breast Cancer Res Treat 2015; 151:373-84
Leyland-Jones Brian, Neven Patrick, Treilleux Isabelle, Rasmussen Birgitte Bruun, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Pagani Olivia, Viale Giuseppe, Rae James M, Harvey Vernon J, Ditzel Henrik J, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Lyng Maria B, Regan Meredith M
Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
Desax M, Hundsberger T, Rothermundt C, Omlin A, Gillessen Sommer S. Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. Clin Genitourin Cancer 2015; 13:e385-6.
May 1, 2015Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
May 1, 2015Clin Genitourin Cancer 2015; 13:e385-6
Desax Marie-Claire, Hundsberger Thomas, Rothermundt Christian, Omlin Aurelius, Gillessen Sommer Silke
Improved survival of older patients with multiple myeloma in the era of novel agents
Mey U, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34:217-223.
Apr 21, 2015Improved survival of older patients with multiple myeloma in the era of novel agents
Apr 21, 2015Hematol Oncol 2015; 34:217-223
Mey Ulrich J M, Leitner Christoph, Driessen Christoph, Cathomas Richard, Klingbiel Dirk, Hitz Felicitas
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PloS one 2015; 10:e0123435.
Apr 17, 2015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Apr 17, 2015PloS one 2015; 10:e0123435
Varga Zsuzsanna, Cassoly Estelle, Li Qiyu, Öhlschlegel Christian, Tapia Coya, Lehr Hans Anton, Klingbiel Dirk, Thürlimann Beat, Ruhstaller Thomas
Automatic quantification of angiogenesis in 2D sections: a precise and timesaving approach.
Weisshaupt C, Covi J, Hilgert J, Leibig N, Arkudas A, Horch R, Kneser U, Schmidt V. Automatic quantification of angiogenesis in 2D sections: a precise and timesaving approach. J Microsc 2015; 259:185-96.
Apr 16, 2015Automatic quantification of angiogenesis in 2D sections: a precise and timesaving approach.
Apr 16, 2015J Microsc 2015; 259:185-96
Weisshaupt Christian, Covi J M, Hilgert J G, Leibig Nico, Arkudas Andreas, Horch R E, Kneser Ulrich, Schmidt Volker
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Zaman K, Rondeau S, Hawle H, Rudolf C, Perey L, Wiliders H, Berset C, Mueller A, Rochlitz C, Hasler-Strub U, Mamot C, Winterhalder R, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015; 51:1212-20.
Apr 16, 2015Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Apr 16, 2015Eur J Cancer 2015; 51:1212-20
Zaman Khalil, Rondeau Stephanie, Hawle Hanne, Rudolf Christine Biaggi, Perey Lucien, Wiliders Hans, Berset Catherine, Mueller Andreas, Rochlitz Christoph, Hasler-Strub Ursula, Mamot Christoph, Winterhalder Ralph, Neven Patrick
Soft tissue sarcomas of the kidney
Koehle O, Abt D, Rothermundt C, Öhlschlegel C, Brugnolaro C, Schmid H. Soft tissue sarcomas of the kidney. Rare Tumors 2015; 7:5635.
Mar 31, 2015Soft tissue sarcomas of the kidney
Mar 31, 2015Rare Tumors 2015; 7:5635
Koehle Olivia, Abt Dominik, Rothermundt Christian, Öhlschlegel Christian, Brugnolaro C, Schmid Hans-Peter
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Hanusch C, Burchardi N, Engels K, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Untch M, Loibl S, Schneeweiss A, von Minckwitz G. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res 2015; 21:2924-31.
Mar 30, 2015Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Mar 30, 2015Clin Cancer Res 2015; 21:2924-31
Hanusch Claus, Burchardi Nicole, Engels Knut, Blohmer Jens Uwe, Costa Serban, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hilfrich Jörn, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Untch Michael, Loibl Sibylle, Schneeweiss Andreas, von Minckwitz Gunter
Nerve sonography guided diagnosis of painful peroneal palsies caused by in-traneural ganglia- a case series
Hundsberger T (2015). Nerve sonography guided diagnosis of painful peroneal palsies caused by in-traneural ganglia- a case series.
Mar 19, 2015Nerve sonography guided diagnosis of painful peroneal palsies caused by in-traneural ganglia- a case series
Mar 19, 201559. Wissenschaftliche Jahrestagung der DGKN
Hundsberger Thomas
Erythropoietin receptor mutation--a rush of blood to the head?
Holbro A, Skoda R, Lundberg P, Passweg J, Buser A, Lehmann T. Erythropoietin receptor mutation--a rush of blood to the head?. Ann Hematol 2015; 94:1229-31.
Mar 14, 2015Erythropoietin receptor mutation--a rush of blood to the head?
Mar 14, 2015Ann Hematol 2015; 94:1229-31
Holbro Andreas, Skoda Radek C, Lundberg Pontus, Passweg Jakob, Buser Andreas, Lehmann Thomas
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015
Mar 12, 2015Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Mar 12, 2015Cancer Chemother Pharmacol 2015
Kraff Stefanie, Nieuweboer Annemieke J M, Mathijssen Ron H J, Baty Florent, de Graan Anne-Joy, van Schaik Ron H N, Jaehde Ulrich, Jörger Markus
Cetuximab induced aseptic meningitis.
Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer A. Cetuximab induced aseptic meningitis. J Clin Neurosci 2015; 22:1061-3.
Mar 11, 2015Cetuximab induced aseptic meningitis.
Mar 11, 2015J Clin Neurosci 2015; 22:1061-3
Ulrich A, Weiler S, Weller M, Rordorf Tamara, Tarnutzer A A
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Jörger M, van Schaik R, Becker M, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015
Mar 10, 2015Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Mar 10, 2015Prostate Cancer Prostatic Dis 2015
Jörger Markus, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer Silke, Rothermundt Christian